Vyant Bio, Inc.

and conference call. Yesterday, May 17, 2021, the company filed its Q1 quarterly report on Form 10Q and issued a press release summarizing its results and providing an overview of the activities in the first quarter. Today's discussion is being recorded and will be available for replay. A replay of today's webcast will be available on the Bio and Bio website following today's call. Alternatively, the links can be sent to you by contacting IR at buyandbio.com. All participants on this call will be in a listen-only mode during the presentation. The presentation will be followed by a question and answer session. And at this time, I would like to turn the conference over to Jay Roberts, Chief Executive Officer of Buy and Bio. Please go ahead, sir.

Thank you, Operator. And thank you all for joining the Buy and Bio Q1 Investor Webcast. conference call. We're pleased to be in full swing now with our merger activities are completed, and we're focused on executing on our business plan. It's also a great pleasure to speak with you today to share our enthusiasm and to give you some insight into how we envision the near-term future of ViantBio, along with the financial results of the merger we completed on March 30, 2021. On the call with me today is ViantBio's Chief Innovation Officer, Ping Yeh, and our Chief Financial Officer, Andy LaFrance. Following the safe harbor statement, I will provide a strategic overview and update on recent corporate developments, and Andy will take us through a brief financial update and discuss key accounting matters related to the merger. I will then make some closing remarks, and we'll then have Ping available with Andy and me to take your questions. I'll now turn the call over to our CFO, Andy LaFrance.

Thank you, Jay, and welcome to all. We would like to remind you that various comments about future expectations, plans, and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Bio cautions that these forward-looking statements are subject to risks and uncertainties that may cause our actual results to differ materially from those indicating clean risks described in the company's filings with the SEC. Any forward-looking statements made on this conference call speak only as of today's date, Tuesday, May 18, 2021, and Viant Bio does not intend to update any of these forward-looking statements to reflect the events or circumstances that would cause, that would occur after today's date. This conference call is being recorded for audio rebroadcast on Viant Bio's website at www.viantbio.com. With that, I would like to turn the call back over to Jay Roberts. Jay.